{
    "abstract": "To assess the safety profile of antegrade mitomycin gel instillation through a percutaneous nephrostomy tube (PCNT) for upper tract urothelial carcinoma (UTUC) with the aim of decreasing morbidity associated with therapy.\nPatients undergoing antegrade administration of mitomycin gel via PCNT were retrospectively included for analysis from four tertiary referral centres between 2020 and 2022. The primary outcome was safety profile, as graded by Common Terminology Criteria for Adverse Events (v5.0). Post-therapy disease burden was assessed by primary disease evaluation (PDE) via ureteroscopy.\nThirty-two patients received at least one dose of mitomycin gel via PCNT for UTUC, 29 of whom completed induction and underwent PDE. Thirteen patients (41%) had residual tumour present prior to induction therapy. At a median of 15.0\u00a0months following first dose of induction therapy, ureteric stenosis occurred in three patients (9%), all of whom were treated without later recurrence or chronic stenosis. Other adverse events included fatigue (27%), flank pain (19%), urinary tract infection (12%), sepsis (8%) and haematuria (8%). No patients had impaired renal function during follow-up and there were no treatment-related deaths. Seventeen patients (59%) had no evidence of disease at PDE and have not experienced recurrence at a median follow-up of 13.0\u00a0months post induction.\nAdministration of mitomycin gel via a PCNT offers a low rate of ureteric stenosis, demonstrates a favourable safety profile, and is administered without general anaesthesia.",
    "authors": [
        {
            "affiliation": "Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.",
            "firstname": "Kyle M",
            "initials": "KM",
            "lastname": "Rose"
        },
        {
            "affiliation": "Department of Urology, Mayo Clinic Arizona, Scottsdale, AZ, USA.",
            "firstname": "Gopal",
            "initials": "G",
            "lastname": "Narang"
        },
        {
            "affiliation": "Division of Urology, Department of Surgery, University of Missouri, Columbia, MO, USA.",
            "firstname": "Geoffrey",
            "initials": "G",
            "lastname": "Rosen"
        },
        {
            "affiliation": "Department of Urologic Oncology, MD Anderson Cancer Center, Houston, TX, USA.",
            "firstname": "Craig",
            "initials": "C",
            "lastname": "Labatte"
        },
        {
            "affiliation": "Department of Anesthesiology, Mayo Clinic Arizona, Scottsdale, AZ, USA.",
            "firstname": "Catalina I",
            "initials": "CI",
            "lastname": "Dumitrascu"
        },
        {
            "affiliation": "Department of Urology, Mayo Clinic Arizona, Scottsdale, AZ, USA.",
            "firstname": "Justin",
            "initials": "J",
            "lastname": "Campagna"
        },
        {
            "affiliation": "Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.",
            "firstname": "Alice",
            "initials": "A",
            "lastname": "Yu"
        },
        {
            "affiliation": "Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.",
            "firstname": "Brandon J",
            "initials": "BJ",
            "lastname": "Manley"
        },
        {
            "affiliation": "Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.",
            "firstname": "Phillippe E",
            "initials": "PE",
            "lastname": "Spiess"
        },
        {
            "affiliation": "Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.",
            "firstname": "Roger",
            "initials": "R",
            "lastname": "Li"
        },
        {
            "affiliation": "Department of Urologic Oncology, MD Anderson Cancer Center, Houston, TX, USA.",
            "firstname": "Mehrad",
            "initials": "M",
            "lastname": "Adibi"
        },
        {
            "affiliation": "Division of Urology, Department of Surgery, University of Missouri, Columbia, MO, USA.",
            "firstname": "Katie S",
            "initials": "KS",
            "lastname": "Murray"
        },
        {
            "affiliation": "Department of Genitourinary Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA.",
            "firstname": "Wade J",
            "initials": "WJ",
            "lastname": "Sexton"
        },
        {
            "affiliation": "Department of Urology, Mayo Clinic Arizona, Scottsdale, AZ, USA.",
            "firstname": "Mitchell R",
            "initials": "MR",
            "lastname": "Humphreys"
        }
    ],
    "conclusions": null,
    "copyrights": "\u00a9 2022 The Authors. BJU International published by John Wiley & Sons Ltd on behalf of BJU International.",
    "doi": "10.1111/bju.15925",
    "journal": "BJU international",
    "keywords": [
        "#uroonc",
        "#utuc",
        "chemoablation",
        "mitomycin gel",
        "nephrostomy",
        "upper tract urothelial carcinoma"
    ],
    "methods": null,
    "publication_date": "2022-10-27",
    "pubmed_id": "36285629",
    "results": "Thirty-two patients received at least one dose of mitomycin gel via PCNT for UTUC, 29 of whom completed induction and underwent PDE. Thirteen patients (41%) had residual tumour present prior to induction therapy. At a median of 15.0\u00a0months following first dose of induction therapy, ureteric stenosis occurred in three patients (9%), all of whom were treated without later recurrence or chronic stenosis. Other adverse events included fatigue (27%), flank pain (19%), urinary tract infection (12%), sepsis (8%) and haematuria (8%). No patients had impaired renal function during follow-up and there were no treatment-related deaths. Seventeen patients (59%) had no evidence of disease at PDE and have not experienced recurrence at a median follow-up of 13.0\u00a0months post induction.",
    "title": "Antegrade administration of mitomycin gel for upper tract urothelial carcinoma via percutaneous nephrostomy tube: a multi-institutional retrospective cohort study.",
    "xml": "<Element 'PubmedArticle' at 0x788504ca9da0>"
}